Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Ontology highlight
ABSTRACT: Although mast cells (MC) play an important role in allergic reactions, their physiologic role remains unknown. In mice, several models of MC-deficiency have been developed. However, no comparable human model is available. We examined the in vitro- and in vivo effects of the KIT-targeting drug imatinib on growth and development of human MC. Imatinib was found to inhibit stem cell factor (SCF)-induced differentiation of MC in long-term suspension cultures (IC50: 0.01 µM). Correspondingly, long-term treatment of chronic myeloid leukemia (CML) patients with imatinib (400 mg/day) resulted in a marked decrease in MC. In patients with continuous complete molecular response during therapy, bone marrow MC decreased to less than 5% of pre-treatment values, and also serum tryptase concentrations decr
SUBMITTER: Cerny-Reiterer S
PROVIDER: S-EPMC4413638 | biostudies-literature | 2015 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA